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Primary myelofibrosis (PMF) is characterized by abnormal megakaryocyte (Mk) 
development, fibrosis and ineffective hematopoiesis in the marrow and hematopoie-
sis in extramedullary sites [1]. Studies in animal models have suggested that fibro-
sis is established by fibroblasts activated by TGF-β1 released by the abnormal Mk. 
Increased levels of TGF-β1 expression in Mk have been implicated in the develop-
ment of PMF. To clarify whether TGF-β1 alterations are involved in the develop-
ment of PMF in Gata1low mice, the TGF-β1 content of Mk from the marrow and 
spleen from PMF patients and Gata1low mice was compared, the TGF-β1 pathway 
of the marrow and spleen of the Gata1low mouse PMF model was profiled and the 
consequences of pharmacological inhibition of TGF-β1 signaling, obtained through 
treatment with SB431542, was determined. Bone marrow (BM) sections from PMF 
patients contain 4-times more Mk than those from normal donors and great numbers 
of Mk are also detectable in their spleen. In addition, Mk from both BM and spleen 
of PMF patients reacted 34-times more intensely than normal Mk with the TGF-b1 
antibody. Similarly the number of Mk in BM and spleen of Gata-1low mice was 2-3-
fold greater than normal and these cells reacted 3-8-times more intensely with the 
TGF-b1 antibody than wild-type(wt)Mk. These results were confirmed by immunoe-
lectron-microscopy. On average, one Mk from wild-type and Gata1low mice contained 
10.3±2.2 and 54.3±6.5 immunogold-particles per area (p<0.01). SB431542-treatment 
reduced the intensity of TGF-b1 staining of Gata1low Mk both in BM (5.3±1.1) and 
spleen (9.2±0.7) compared to Mk both in BM (18.9±0.8) and spleen (24.3±0.9) of Gata-
1low vehicle-treated mice, while had modest effects on the expression of VEGF and 
CXCL12. Inhibition of TGF-b1 signaling activates hematopoiesis in BM while reduc-
ing extramedullary hematopoiesis in spleen of Gata-1low mice. In addition, it reduced 
fibrosis, vessel microdensity, increases Ptl counts and decreases WBC and poikilo-
cytes in the blood of Gata1low mice suggesting a potential benefit for treatments tar-
geting microenvironment abnormalities in PMF.
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